Trial Profile
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Nalmefene (Primary)
- Indications Alcoholism
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 02 May 2020 Results published in the Psychiatry and Clinical Neurosciences
- 10 Apr 2018 Status changed from active, no longer recruiting to completed.
- 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.